A dose escalation study of ORG 10172 (Low molecular weight heparinoid) in stroke

J. Biller, E. W. Massey, J. R. Marler, H. P. Adam, J. N. Davis, Askiel Bruno, R. A. Henriksen, R. J. Linhardt, L. B. Goldstein, M. Alberts, C. T. Kisker, G. J. Toffol, C. S. Greenberg, K. J. Banwart, C. Bertels, D. W. Beck, M. Walker, H. N. Magnani

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

An intravenous infusion of a low molecular weight heparinoid, with a reduced risk of hemorrhage, may be an alternative to heparin in the management of acute ischemic stroke. To evaluate this hypothesis, we studied the safety of the heparinoid, ORG 10172, in a dose-escalation study in 26 patients. The drug was administered as a loading bolus followed by a 7-day infusion in five rates with target anti-factor Xa levels from 0.2 to 1.0 U/ml. The drug was well tolerated; no major bleeding complications or thrombocytopenia occurred. There were no deaths or hemorrhagic transformation of cerebral infarctions. The results indicate that ORG 10172 at doses to achieve a level of 1.0 U/ml or less may be used safely in management of acute cerebral infarction.

Original languageEnglish (US)
Pages (from-to)262-265
Number of pages4
JournalNeurology
Volume39
Issue number2
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Heparinoids
Cerebral Infarction
Molecular Weight
Stroke
Hemorrhage
Factor Xa
Intravenous Infusions
Thrombocytopenia
Pharmaceutical Preparations
Heparin
Safety

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Biller, J., Massey, E. W., Marler, J. R., Adam, H. P., Davis, J. N., Bruno, A., ... Magnani, H. N. (1989). A dose escalation study of ORG 10172 (Low molecular weight heparinoid) in stroke. Neurology, 39(2), 262-265.

A dose escalation study of ORG 10172 (Low molecular weight heparinoid) in stroke. / Biller, J.; Massey, E. W.; Marler, J. R.; Adam, H. P.; Davis, J. N.; Bruno, Askiel; Henriksen, R. A.; Linhardt, R. J.; Goldstein, L. B.; Alberts, M.; Kisker, C. T.; Toffol, G. J.; Greenberg, C. S.; Banwart, K. J.; Bertels, C.; Beck, D. W.; Walker, M.; Magnani, H. N.

In: Neurology, Vol. 39, No. 2, 01.01.1989, p. 262-265.

Research output: Contribution to journalArticle

Biller, J, Massey, EW, Marler, JR, Adam, HP, Davis, JN, Bruno, A, Henriksen, RA, Linhardt, RJ, Goldstein, LB, Alberts, M, Kisker, CT, Toffol, GJ, Greenberg, CS, Banwart, KJ, Bertels, C, Beck, DW, Walker, M & Magnani, HN 1989, 'A dose escalation study of ORG 10172 (Low molecular weight heparinoid) in stroke', Neurology, vol. 39, no. 2, pp. 262-265.
Biller J, Massey EW, Marler JR, Adam HP, Davis JN, Bruno A et al. A dose escalation study of ORG 10172 (Low molecular weight heparinoid) in stroke. Neurology. 1989 Jan 1;39(2):262-265.
Biller, J. ; Massey, E. W. ; Marler, J. R. ; Adam, H. P. ; Davis, J. N. ; Bruno, Askiel ; Henriksen, R. A. ; Linhardt, R. J. ; Goldstein, L. B. ; Alberts, M. ; Kisker, C. T. ; Toffol, G. J. ; Greenberg, C. S. ; Banwart, K. J. ; Bertels, C. ; Beck, D. W. ; Walker, M. ; Magnani, H. N. / A dose escalation study of ORG 10172 (Low molecular weight heparinoid) in stroke. In: Neurology. 1989 ; Vol. 39, No. 2. pp. 262-265.
@article{3caeaf6386ed49818d0600887a5cb8d3,
title = "A dose escalation study of ORG 10172 (Low molecular weight heparinoid) in stroke",
abstract = "An intravenous infusion of a low molecular weight heparinoid, with a reduced risk of hemorrhage, may be an alternative to heparin in the management of acute ischemic stroke. To evaluate this hypothesis, we studied the safety of the heparinoid, ORG 10172, in a dose-escalation study in 26 patients. The drug was administered as a loading bolus followed by a 7-day infusion in five rates with target anti-factor Xa levels from 0.2 to 1.0 U/ml. The drug was well tolerated; no major bleeding complications or thrombocytopenia occurred. There were no deaths or hemorrhagic transformation of cerebral infarctions. The results indicate that ORG 10172 at doses to achieve a level of 1.0 U/ml or less may be used safely in management of acute cerebral infarction.",
author = "J. Biller and Massey, {E. W.} and Marler, {J. R.} and Adam, {H. P.} and Davis, {J. N.} and Askiel Bruno and Henriksen, {R. A.} and Linhardt, {R. J.} and Goldstein, {L. B.} and M. Alberts and Kisker, {C. T.} and Toffol, {G. J.} and Greenberg, {C. S.} and Banwart, {K. J.} and C. Bertels and Beck, {D. W.} and M. Walker and Magnani, {H. N.}",
year = "1989",
month = "1",
day = "1",
language = "English (US)",
volume = "39",
pages = "262--265",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A dose escalation study of ORG 10172 (Low molecular weight heparinoid) in stroke

AU - Biller, J.

AU - Massey, E. W.

AU - Marler, J. R.

AU - Adam, H. P.

AU - Davis, J. N.

AU - Bruno, Askiel

AU - Henriksen, R. A.

AU - Linhardt, R. J.

AU - Goldstein, L. B.

AU - Alberts, M.

AU - Kisker, C. T.

AU - Toffol, G. J.

AU - Greenberg, C. S.

AU - Banwart, K. J.

AU - Bertels, C.

AU - Beck, D. W.

AU - Walker, M.

AU - Magnani, H. N.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - An intravenous infusion of a low molecular weight heparinoid, with a reduced risk of hemorrhage, may be an alternative to heparin in the management of acute ischemic stroke. To evaluate this hypothesis, we studied the safety of the heparinoid, ORG 10172, in a dose-escalation study in 26 patients. The drug was administered as a loading bolus followed by a 7-day infusion in five rates with target anti-factor Xa levels from 0.2 to 1.0 U/ml. The drug was well tolerated; no major bleeding complications or thrombocytopenia occurred. There were no deaths or hemorrhagic transformation of cerebral infarctions. The results indicate that ORG 10172 at doses to achieve a level of 1.0 U/ml or less may be used safely in management of acute cerebral infarction.

AB - An intravenous infusion of a low molecular weight heparinoid, with a reduced risk of hemorrhage, may be an alternative to heparin in the management of acute ischemic stroke. To evaluate this hypothesis, we studied the safety of the heparinoid, ORG 10172, in a dose-escalation study in 26 patients. The drug was administered as a loading bolus followed by a 7-day infusion in five rates with target anti-factor Xa levels from 0.2 to 1.0 U/ml. The drug was well tolerated; no major bleeding complications or thrombocytopenia occurred. There were no deaths or hemorrhagic transformation of cerebral infarctions. The results indicate that ORG 10172 at doses to achieve a level of 1.0 U/ml or less may be used safely in management of acute cerebral infarction.

UR - http://www.scopus.com/inward/record.url?scp=0024501894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024501894&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 262

EP - 265

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -